How researchers are using the Maxpar Direct Immune Profiling Assay
Fluidigm CyTOF® technology with the Maxpar® Direct™ Immune Profiling Assay™ provide best-in-class immune monitoring with the cost, flexibility and consistency needed for standardized immune monitoring.
Look through the publications, preprints and clinical trials listed below to see the number of ways that researchers are using the assay to advance their studies of COVID-19 and other diseases and conditions.
Learn how the Maxpar Direct Immune Profiling System addresses the challenges of longitudinal immune monitoring studies and is being used in COVID-19 research.
Read the Spotlight article on Benjamin Terrier, lead author of this publication, to see how his lab used this immune profiling assay to define a distinct immune response phenotype in severe and critically ill COVID-19 patients that could help identify high-risk individuals.
“Analyzing the immune response of patients … by mass cytometry allows us to cover the innate and adaptive immune responses simultaneously. Not only could we analyze immune cells, but also cytokine production and the transcriptional signatures in these patients. Essentially, we could look at everything in the whole blood.”
— Benjamin Terrier, MD, PhD, University of Paris
Researchers at the Icahn School of Medicine at Mount Sinai have developed a streamlined workflow for whole blood staining with the Maxpar Direct Immune Profiling Assay that will be used to perform standardized longitudinal immune monitoring on 2,000 COVID-19 patients.
The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) clinical study (NCT04378777) is a prospective observational cohort surveillance study of up to 2,000 adult participants hospitalized with known or presumptive COVID-19. Detailed analysis of the immunophenotypic and genomic data collected will be used to identify key features of COVID-19 disease susceptibility and/or progression.
Two key advantages make mass cytometry ideal for gathering this data: the ability to stain, freeze and ship samples processed with the Maxpar Direct Immune Profiling Assay to a centralized location for processing on a mass cytometer and the ability to analyze small sample sizes, such as endotracheal aspirates.
A large collaboration led by the research university KU Leuven and University Hospital Leuven has initiated the COntAGIouS trial (COVID-19 Advanced Genetic and Immunologic Sampling), an in-depth characterization of the dynamic host immune response to coronavirus SARS-CoV-2.
What makes this study so significant is the multiplexing approach, simultaneously analyzing different cells, proteins and RNA biomarkers in blood samples, with the objective to dive into the unknowns of COVID-19. CyTOF technology, together with the Maxpar Direct Immune Profiling Assay, plays an important role in the trial, helping the team to observe the different immune system players and their interactions in COVID-19 patient samples.
A multi-institutional collaborative study in the United Kingdom is using the Maxpar Direct Immune Profiling Assay for participant immunomonitoring in a clinical trial for major depressive disorder.
Patients who have not responded to conventional antidepressant drugs will be treated with an anti-inflammatory drug to reduce stress-related depression. The assay will be used to assess changes in peripheral blood at baseline and after eight weeks of daily treatment.
Lori Turner, a researcher at the University of Cambridge, is using the Maxpar Direct Immune Profiling system in this clinical study.